App-Quantinova.ai

31P MRS and MRI phenotyping of muscle metabolic quality in IBD fatigue

Mcging, J - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Impact of Ulcerative Colitis Symptoms on Daily Life

Dubinsky, M.C - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Unraveling the rewiring of cytokine signalling in Inflammatory Bowel Disease using a novel network biology approach

Olbei, M - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory bowel disease

N/A

Views of patients with Inflammatory Bowel Disease on their care during COVID-19 pandemic

Klimova, K - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

An audit of quality of histopathology reporting of colorectal mucosal biopsies for the diagnosis and assessment of Inflammatory Bowel Disease.

Mcalinn, J - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Initial response to induction treatment more important than type of induction treatment for achieving sustained steroid free remission at 1 year in new-onset paediatric Crohn’s disease

Klomberg, R - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Crohn's disease

N/A

Prioritising colonoscopy by faecal immunochemical test result does not delay the diagnosis of inflammatory bowel disease

White, K - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Rationalizing colonoscopy utilization for Inflammatory bowel disease diagnosis: time to reset the Calprotectin threshold to >600?

Desoki, R - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Impact of disease location on burden of illness in patients with moderate-severe Crohn’s disease: A real-world survey in the United States, France, Germany, Italy, Spain, and United Kingdom (5EU)

Sikirica, M - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

The impact of seton use on clinical and patient-reported outcomes in Crohn’s disease perianal fistulas: findings from a systematic literature review

White, I - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Incidence and significance of vitamin D deficiency at Inflammatory Bowel Disease inception in the COVID era

Rimmer, P - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Inflammatory bowel disease

N/A

PSC/IBD and IBD have similar type and location of colonic lesions, but Dye ChromoEndoscopy (DCE) increases detection rate compared to White Light Endoscopy (WLE)

Labarile, N - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Inflammatory bowel disease

N/A

Correlation of the IBD Disk scores with diagnosis of IBD, Faecal calprotectin and Endoscopic scores in patients presenting to a rapid access IBD inception clinic.

Shariff , S - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Pre-treatment antibodies to infliximab and adalimumab are common but are not associated with anti-TNF treatment failure

Nice, R - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Adalimumab

Anogenital Crohn’s disease and granulomatosis: A systematic review of epidemiology, clinical manifestations, and treatment

Honap, S - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

An inflammatory serum metabolomic signature predicts response to vedolizumab treatment in people with Crohn’s Disease

Radford-Smith, D - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Entyvio

Persistent burden of disease in patients with Crohn’s disease treated with biologic therapy: results from a real-world survey in the United States (US), France, Germany, Italy, Spain, and United Kingdom (5EU)

Sikirica, M - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Are we doing enough to prevent colectomy in Inflammatory Bowel Disease (IBD) patients? A 5-year review of colectomy rates in Shropshire and Mid-Wales UK (2015-2019).

Javed, A - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Autoimmune pancreatitis in patients with Inflammatory Bowel Disease: results from a multicentre ECCO CONFER cases series

Eder, P.M - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Burden of bowel urgency across specific treatment groups among Ulcerative Colitis patients – real world global study analyses

Atreya, R - European Crohn’s and Colitis Organisation (ECCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory bowel disease

N/A

Filters

45280 Abstracts